Patient‑Reported Late Effects in Allogeneic Hematopoietic Stem Cell Transplantation Survivorship: A Nationwide Population‑Based Study.

Authors

Mette Schaufuss Engedal, Kristina Nørskov, Anders Tolver, Lea Brandt Kristensen, Astrid Lindman, Gitte Olesen, Brian Thomas Kornblit, Christoffer Johansen, Mary Jarden

Published in

Transplantation and cellular therapy. Oct 11, 2026. Epub Oct 11, 2026.

Abstract

Survivorship after allogeneic hematopoietic stem‑cell transplantation (allo‑HCT) is associated with late effects and chronic graft‑versus‑host disease (cGVHD), but population‑level data on patient‑reported outcomes remain limited.
To characterize the multidimensional burden of patient-reported late effects in a nationwide cohort of allo-HCT survivors, compare health-related quality of life (HRQOL) with Danish population reference values, and identify symptoms and functional impairments exceeding thresholds for clinical importance.
In this nationwide, population-based cross-sectional study, adult allo-HCT survivors transplanted in Denmark between 1973 and 2024 were identified through transplant databases and registry linkage. Participants completed the EORTC Survivorship Questionnaire (QLQ-SURV100). QLQ-C30-equivalent HRQOL scores were compared with age- and sex-stratified Danish population reference values, and thresholds for clinical importance were applied.
Of 1333 eligible survivors, 895 participated (67%). Median age was 64 years (range, 21-84), and median time since transplantation was 7 years (range, 0-44). Participants reported a mean of 18 concurrent symptoms, including 8 of moderate-to-high severity; only 1% reported none. Negative health outlook (93%) and fatigue (90%) were the most prevalent late effects. Overall, 91% reported low or moderate sexual functioning, and sexual problems showed the highest severity. Among participants aged ≤67 years, 45% were not working, and loss of income was reported by 54% overall. Participants reported poorer HRQOL than population reference values, and 38% exceeded thresholds for clinical importance in at least 5 domains.
Allo-HCT survivorship is characterized by multiple concurrent symptoms and impairments, demonstrating a substantial population-level burden with implications for long-term survivorship care.
ClinicalTrials.gov, NCT06277479.

PMID:
42860152
Bibliographic data and abstract were imported from PubMed on 12 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.